Navigation Links
Perrigo Confirms FDA Approval For Testosterone Gel 1%
Date:2/5/2013

ALLEGAN, Mich., Feb. 5, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) announced that it has received U.S. Food and Drug Administration approval for its New Drug Application (NDA) for testosterone gel 1%. Perrigo's NDA included a bioequivalence study that compared its product to AbbVie's AndroGel® 1%.

(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

AndroGel® 1% (testosterone gel 1%) is indicated to treat adult males who have low or no testosterone. Annual sales were approximately $705 million annually, as measured by Symphony Health.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This filing is another example of our investment in new products and continued focus on bringing extended topicals to market. As always, Perrigo is committed to making quality healthcare more affordable for our customers and consumers."          

From its beginnings as a packager of generic home remedies in 1887, Allegan, Michigan-based Perrigo Company has grown to become a leading global provider of quality, affordable healthcare products. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, dietary supplements and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of logistics operations have evolved over the years to include the United States, Israel, Mexico, the United Kingdom, India, China and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2012, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Reports Record Second Quarter Revenue, Adjusted Earnings and Operating Cash Flow
2. Perrigo Company To Acquire OTC Companion Animal Health Company, Velcera, Inc., For $160 Million
3. Perrigo Commences Launch Of Clobetasol Emulsion Propionate Foam, 0.05%
4. Perrigo Company To Release Second Quarter Fiscal Year 2013 Results On February 1, 2013
5. Perrigo Company Announces The Appointment Of Industry Veteran To Executive Vice President And General Manager, Rx
6. Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam 0.12%
7. Perrigo Company To Present At The Credit Suisse Healthcare Conference
8. Perrigo Reports Record First Quarter Revenue And Adjusted Earnings And Raises Full Year Adjusted EPS Guidance
9. Perrigo Company Announces Appointment Of New Board Of Directors Member
10. Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million
11. Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , Dec. 7, 2016  The Corporate ... healthcare manager to call them anytime at 866-714-6466 if ... managers to sell more drugs. Aside from the innocent ... taxpayers as well, because often-times these practices target Medicare recipients ... http://photos.prnewswire.com/prnh/20161206/446240 ...
(Date:12/7/2016)... READING, Mass. , Dec. 7, 2016 /PRNewswire/ ... and Trace Network for connecting the Life Sciences ... the global marketplace, today announced that Tjoapack has ... European pharmaceutical manufacturing customers comply with the rapidly ... Chain Security Act (DSCSA) in 2017 and the ...
(Date:12/7/2016)... 2016 According to responses from U.S. oncologists that ... of patients with non-small cell lung cancer (NSCLC), treatment decisions ... genetic mutation status. The findings of the survey were presented ... #P3.02b ) at the 2016 World Conference on Lung ... The survey results revealed an overall high rate of ...
Breaking Medicine Technology:
(Date:12/7/2016)... TX (PRWEB) , ... OCTOBER XX, 2016 (PRWEB) ... ... help solve another mystery. A new study entitled “Canine Filamentous Dermatitis Associated ... disease can occur in dogs. The study was published in the prestigious Journal ...
(Date:12/7/2016)... ... 07, 2016 , ... Texas Premier Locksmith , a ... by unethical locksmith companies and is urging Search Engines to improve verification methods ... Premier Locksmith, these fraudulent locksmith services take advantage of consumers locked out of ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... newest portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare professionals ... the WellnessPro platform by expanding the treatment modalities available in a single ...
(Date:12/7/2016)... ... , ... “Fred Rides a Train” allows readers to tag along on a ... a Train” is the creation of published author, Janet Morrison, who has been writing ... The "Fred, the Dog" series is her first attempt at writing for children. Janet, ...
(Date:12/7/2016)... , ... December 07, 2016 , ... "Hacking into my ... had described him as 'a genius.'" Thus begins "Margaret in Berlin," Book Twelve in ... published by Wyston Books, Inc. These novels narrate the lives of a ...
Breaking Medicine News(10 mins):